The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and activity of blinatumomab for older patients (pts) with relapsed/refractory (R/R) B-precursor acute lymphoblastic leukemia (ALL) in two phase 2 studies.
 
Hagop M. Kantarjian
Research Funding - Amgen (Inst); ARIAD (Inst); Bristol-Myers Squibb (Inst); Delta-Fly Pharma (Inst); Novartis (Inst); Pfizer (Inst)
 
Anthony Selwyn Stein
Honoraria - Amgen
Consulting or Advisory Role - Amgen
Research Funding - Amgen
 
Ralf C. Bargou
Honoraria - Amgen; Novartis; Pfizer
Consulting or Advisory Role - Amgen; Novartis; Pfizer
Patents, Royalties, Other Intellectual Property - Amgen
 
Carlos Grande
Consulting or Advisory Role - Amgen
Speakers' Bureau - Amgen
 
Richard A. Larson
No Relationships to Disclose
 
Matthias Stelljes
No Relationships to Disclose
 
Jonathan Eliot Benjamin
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Catherine Jia
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Max S. Topp
Honoraria - Amgen
Consulting or Advisory Role - Amgen
Patents, Royalties, Other Intellectual Property - Amgen
Travel, Accommodations, Expenses - Amgen; Roche Pharma AG; Takeda